DK55192D0 - 1-piperazino-1,2-dihydroindenderivater - Google Patents

1-piperazino-1,2-dihydroindenderivater

Info

Publication number
DK55192D0
DK55192D0 DK92551A DK55192A DK55192D0 DK 55192 D0 DK55192 D0 DK 55192D0 DK 92551 A DK92551 A DK 92551A DK 55192 A DK55192 A DK 55192A DK 55192 D0 DK55192 D0 DK 55192D0
Authority
DK
Denmark
Prior art keywords
alkyl
hydrogen
cycloalkylalkyl
cycloalkyl
alkenyl
Prior art date
Application number
DK92551A
Other languages
Danish (da)
English (en)
Inventor
Klaus Bogeso
Peter Bregnedal
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Priority to DK92551A priority Critical patent/DK55192D0/da
Publication of DK55192D0 publication Critical patent/DK55192D0/da
Priority to IL105464A priority patent/IL105464A/en
Priority to ZA932840A priority patent/ZA932840B/xx
Priority to DE69328901T priority patent/DE69328901T2/de
Priority to SK1293-94A priority patent/SK281613B6/sk
Priority to JP51884593A priority patent/JP3255416B2/ja
Priority to HU9403098A priority patent/HUT71419A/hu
Priority to DK93909807T priority patent/DK0638073T3/da
Priority to NZ252098A priority patent/NZ252098A/en
Priority to CZ942619A priority patent/CZ281676B6/cs
Priority to ES93909807T priority patent/ES2148227T3/es
Priority to PT93909807T priority patent/PT638073E/pt
Priority to PCT/DK1993/000136 priority patent/WO1993022293A1/en
Priority to KR1019940703815A priority patent/KR100267635B1/ko
Priority to AT93909807T priority patent/ATE194003T1/de
Priority to CA002134566A priority patent/CA2134566C/en
Priority to RU94045948A priority patent/RU2114106C1/ru
Priority to EP93909807A priority patent/EP0638073B1/en
Priority to AU40599/93A priority patent/AU669709B2/en
Priority to FI945042A priority patent/FI113862B/fi
Priority to NO944090A priority patent/NO306946B1/no
Priority to US08/331,213 priority patent/US5807855A/en
Priority to HU95P/P00587P priority patent/HU211909A9/hu
Priority to HK98115090A priority patent/HK1013816A1/xx
Priority to GR20000402086T priority patent/GR3034396T3/el
Priority to CL200302050A priority patent/CL2003002050A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
DK92551A 1992-04-28 1992-04-28 1-piperazino-1,2-dihydroindenderivater DK55192D0 (da)

Priority Applications (26)

Application Number Priority Date Filing Date Title
DK92551A DK55192D0 (da) 1992-04-28 1992-04-28 1-piperazino-1,2-dihydroindenderivater
IL105464A IL105464A (en) 1992-04-28 1993-04-20 Trans-compounds (1-piperazin-1-yl) -3-aryl-1,2-dihydroindene are converted to the 3-position of the piperazine ring and pharmaceutical mixtures containing or
ZA932840A ZA932840B (en) 1992-04-28 1993-04-22 1-piperazino-1,3-dihydroindene derivatives
AU40599/93A AU669709B2 (en) 1992-04-28 1993-04-23 1-piperazino-1,2-dihydroindene derivatives
PCT/DK1993/000136 WO1993022293A1 (en) 1992-04-28 1993-04-23 1-piperazino-1,2-dihydroindene derivatives
AT93909807T ATE194003T1 (de) 1992-04-28 1993-04-23 1-piperazino-1,2-dihydroindenderivate
JP51884593A JP3255416B2 (ja) 1992-04-28 1993-04-23 １‐ピペラジノ‐１，２‐ジヒドロインデン誘導体
HU9403098A HUT71419A (en) 1992-04-28 1993-04-23 1-piperazino-1,2-dihydroindene derivatives and pharmaceutical compositions containing them
DK93909807T DK0638073T3 (da) 1992-04-28 1993-04-23 1-Piperazino-1,2-dihydroindenderivater
NZ252098A NZ252098A (en) 1992-04-28 1993-04-23 1-aryl-3-piperazino indane derivatives and medicaments
CZ942619A CZ281676B6 (cs) 1992-04-28 1993-04-23 1-piperazin-1,2-dihydroindenové deriváty, farmaceutické prostředky s jejich obsahem a použití uvedených látek pro výrobu farmaceutických prostředků
ES93909807T ES2148227T3 (es) 1992-04-28 1993-04-23 Derivados de 1-piperazino-1,2-dihidroindeno.
PT93909807T PT638073E (pt) 1992-04-28 1993-04-23 Derivados de 1-piperazino-1, 2-dihidroindeno
DE69328901T DE69328901T2 (de) 1992-04-28 1993-04-23 1-piperazino-1,2-dihydroindenderivate
KR1019940703815A KR100267635B1 (ko) 1992-04-28 1993-04-23 1-피페라지노-1, 2-디히드로인덴 유도체
SK1293-94A SK281613B6 (sk) 1992-04-28 1993-04-23 Trans-izoméry derivátov 1-piperazín-1,2-dihydroindénu, farmaceutický prípravok s ich obsahom a ich použitie
CA002134566A CA2134566C (en) 1992-04-28 1993-04-23 1-piperazino-1,2-dihydroindene derivatives
RU94045948A RU2114106C1 (ru) 1992-04-28 1993-04-23 Производные транс-изомеров 1-пиперазин-1,2-дигидроиндена
EP93909807A EP0638073B1 (en) 1992-04-28 1993-04-23 1-piperazino-1,2-dihydroindene derivatives
FI945042A FI113862B (fi) 1992-04-28 1994-10-26 Menetelmä uusien terapeuttisesti käyttökelpoisten 1-piperatsino-1,2-dihydroindeenijohdannaisten valmistamiseksi
NO944090A NO306946B1 (no) 1992-04-28 1994-10-27 Trans-isomerer av 1-piperazino-1,2-dihydroindenforbindelser
US08/331,213 US5807855A (en) 1992-04-28 1994-10-28 1-piperazino-1,2-dihydroindene derivatives
HU95P/P00587P HU211909A9 (en) 1992-04-28 1995-06-29 1-piperazino-1,2-dihydroindene derivatives
HK98115090A HK1013816A1 (en) 1992-04-28 1998-12-23 1-Piperazino-1,2-dihydroindene derivatives
GR20000402086T GR3034396T3 (en) 1992-04-28 2000-09-13 1-piperazino-1,2-dihydroindene derivatives.
CL200302050A CL2003002050A1 (es) 1992-04-28 2003-10-10 Compuestos derivados de 1-piperazin-1,2-dihidroindeno, su composicion farmaceutica y el uso de esta para tratar enfermedades del sistema nervioso central.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK92551A DK55192D0 (da) 1992-04-28 1992-04-28 1-piperazino-1,2-dihydroindenderivater

Publications (1)

Publication Number Publication Date
DK55192D0 true DK55192D0 (da) 1992-04-28

Family

ID=8094828

Family Applications (2)

Application Number Title Priority Date Filing Date
DK92551A DK55192D0 (da) 1992-04-28 1992-04-28 1-piperazino-1,2-dihydroindenderivater
DK93909807T DK0638073T3 (da) 1992-04-28 1993-04-23 1-Piperazino-1,2-dihydroindenderivater

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK93909807T DK0638073T3 (da) 1992-04-28 1993-04-23 1-Piperazino-1,2-dihydroindenderivater

Country Status (24)

Country Link
US (1) US5807855A (cs)
EP (1) EP0638073B1 (cs)
JP (1) JP3255416B2 (cs)
KR (1) KR100267635B1 (cs)
AT (1) ATE194003T1 (cs)
AU (1) AU669709B2 (cs)
CA (1) CA2134566C (cs)
CL (1) CL2003002050A1 (cs)
CZ (1) CZ281676B6 (cs)
DE (1) DE69328901T2 (cs)
DK (2) DK55192D0 (cs)
ES (1) ES2148227T3 (cs)
FI (1) FI113862B (cs)
GR (1) GR3034396T3 (cs)
HK (1) HK1013816A1 (cs)
HU (2) HUT71419A (cs)
IL (1) IL105464A (cs)
NO (1) NO306946B1 (cs)
NZ (1) NZ252098A (cs)
PT (1) PT638073E (cs)
RU (1) RU2114106C1 (cs)
SK (1) SK281613B6 (cs)
WO (1) WO1993022293A1 (cs)
ZA (1) ZA932840B (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037398A1 (en) * 2008-10-03 2010-04-08 H. Lundbeck A/S Oral formulation
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
IL157254A0 (en) * 2001-02-23 2004-02-19 Merck & Co Inc N-substituted nonaryl-heterocyclic nmda/mr2b antagonists
CA2467337A1 (en) 2001-12-21 2003-07-10 H. Lundbeck A/S Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors
IS7282A (is) * 2001-12-21 2004-05-21 H. Lundbeck A/S Amínóindan afleiður sem serótónín og noradrenalínupptökuhindrar
PL199016B1 (pl) † 2002-06-20 2008-08-29 Adamed Sp Z Oo Sposób wytwarzania olanzapiny
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
AR045279A1 (es) * 2003-08-18 2005-10-19 Lundbeck & Co As H Trans-1-(6-cloro-3-fenilindan-1-il)-3,3-dimetilpiperazina
BRPI0413595B8 (pt) * 2003-08-18 2021-05-25 H Lundbeck As sal de malonato, composição farmacêutica, uso de um sal de malonato, e, método de fabricação de um composto
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
TWI376373B (en) * 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
MX2007009816A (es) * 2005-02-16 2007-09-07 Lundbeck & Co As H Sales de tartrato y de malato de trans-1-((1r,3s)-6-cloro-3- fenilindan-1-i1)-3,3-dimetilpiperazina.
TWI453198B (zh) * 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
TW200819426A (en) 2006-08-31 2008-05-01 Lundbeck & Co As H Novel indane compounds
BRPI0912223A2 (pt) * 2008-05-07 2015-10-06 Lundbeck & Co As H métodos para melhorar funcionamento cognitivo e para tratar uma doença, composto, uso do mesmo, e, composição farmacêutica.
WO2010125134A1 (en) * 2009-04-30 2010-11-04 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
TW201102370A (en) 2009-07-07 2011-01-16 Lundbeck & Co As H Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl piperazine
JP5941410B2 (ja) 2010-11-09 2016-06-29 株式会社カネカ ハロゲン化インデノン類及びそれを用いた光学活性インダノン類又は光学活性インダノール類の製造方法
JP2014501771A (ja) * 2011-01-07 2014-01-23 ハー・ルンドベック・アクチエゼルスカベット ４−（（１ｒ，３ｓ）−６−クロロ−３−フェニル−インダン−１−イル）−１，２，２−トリメチル−ピペラジンと１−（（１ｒ，３ｓ）−６−クロロ−３−フェニル−インダン，１−イル）−３，３−ジメチル−ピペラジンとを分割するための方法
JP5668177B2 (ja) 2011-06-20 2015-02-12 ハー・ルンドベック・アクチエゼルスカベット 統合失調症の治療のための重水素化１−ピペラジノ−３−フェニルインダン
TWI552751B (zh) 2011-06-20 2016-10-11 Ｈ 朗德貝克公司 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法
MA52183A (fr) * 2018-04-06 2021-02-17 H Lundbeck As Procédé de préparation de 2,2-diméthylpipérazine
CN112930341A (zh) 2018-10-29 2021-06-08 H.隆德贝克有限公司 无定形的具有式(i)的化合物和无定形的具有式(i)的化合物的盐
WO2020114853A1 (en) 2018-12-03 2020-06-11 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038395A (en) * 1973-06-25 1977-07-26 Kefalas A/S Compositions of and method of treating with the alpha-isomer of 2-chloro-9-[3'-(N'-2-hydroxyethylpiperazino-N)-propylidene]-thiaxanthene, carboxylic acid esters thereof and acid addition salts of these compounds
GB1469108A (en) * 1973-06-25 1977-03-30 Kefalas As Thiaxanthene derivative
NZ196284A (en) * 1980-02-29 1983-12-16 Kefalas As 1-piperazino-3-phenylindane derivatives:pharmaceutical compositions
IE55972B1 (en) * 1982-10-07 1991-03-13 Kefalas As Phenylindene derivatives,acid addition salts thereof,and methods of preparation
HU198036B (en) * 1983-08-22 1989-07-28 Hoechst Roussel Pharma Process for production of derivatives of 3-piperidil-/1h/-indasole and medical preparatives containing them
GB8427125D0 (en) * 1984-10-26 1984-12-05 Lundbeck & Co As H Organic compounds
WO1986003601A1 (en) * 1984-12-03 1986-06-19 Hughes Aircraft Company Variable lens and birefringence compensator for continuous operation
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
DE3521761A1 (de) * 1985-06-19 1987-01-02 Bayer Ag Neue 1,4-dihydropyridine, verfahren zur herstellung und ihre verwendung in arzneimitteln
GB8628644D0 (en) * 1986-12-01 1987-01-07 Lunbeck A S H Intermediates
GB8704572D0 (en) * 1987-02-26 1987-04-01 Lundbeck & Co As H Organic compounds
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
EP0302423A3 (en) * 1987-08-07 1991-01-09 Hoechst-Roussel Pharmaceuticals Incorporated 1-phenyl-3-(1-piperazinyl)-1h-indazoles, a process and intermediates for their preparation, and the use thereof as medicaments
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
GB8830312D0 (en) * 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
CA2071897A1 (en) * 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
DK152090D0 (da) * 1990-06-22 1990-06-22 Lundbaek A S H Piperidylsubstituerede indolderivater
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
DK286990D0 (da) * 1990-12-04 1990-12-04 Lundbeck & Co As H Indanderivater
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives

Also Published As

Publication number Publication date
FI945042A (fi) 1994-10-26
CL2003002050A1 (es) 2005-01-07
HU9403098D0 (en) 1994-12-28
ATE194003T1 (de) 2000-07-15
PT638073E (pt) 2000-11-30
ZA932840B (en) 1993-11-23
CZ281676B6 (cs) 1996-12-11
SK281613B6 (sk) 2001-05-10
US5807855A (en) 1998-09-15
CA2134566C (en) 2004-08-10
KR100267635B1 (ko) 2000-11-01
ES2148227T3 (es) 2000-10-16
FI113862B (fi) 2004-06-30
EP0638073B1 (en) 2000-06-21
JPH07505895A (ja) 1995-06-29
WO1993022293A1 (en) 1993-11-11
SK129394A3 (en) 1995-05-10
DE69328901D1 (de) 2000-07-27
CA2134566A1 (en) 1993-11-11
EP0638073A1 (en) 1995-02-15
CZ261994A3 (en) 1995-05-17
NO944090D0 (no) 1994-10-27
NO306946B1 (no) 2000-01-17
IL105464A (en) 1998-01-04
HU211909A9 (en) 1996-01-29
HK1013816A1 (en) 1999-09-10
AU669709B2 (en) 1996-06-20
KR950701323A (ko) 1995-03-23
AU4059993A (en) 1993-11-29
DE69328901T2 (de) 2001-01-11
RU2114106C1 (ru) 1998-06-27
RU94045948A (ru) 1996-09-10
NZ252098A (en) 1996-05-28
FI945042A0 (fi) 1994-10-26
DK0638073T3 (da) 2000-11-06
HUT71419A (en) 1995-11-28
JP3255416B2 (ja) 2002-02-12
GR3034396T3 (en) 2000-12-29
IL105464A0 (en) 1993-08-18
NO944090L (no) 1994-12-20

Similar Documents

Publication Publication Date Title
DE69328901D1 (de) 1-piperazino-1,2-dihydroindenderivate
BR9206500A (pt) Heterociclos contendo, nitrogênio tricíclico condensado como antagonistas de substancia receptora P
AR016129A1 (es) Compuestos derivados de 5h-tiazolo[3,2-a]pirimidina; su uso, un procedimiento para prepararlos, medicamentos que los contienen y compuestos utiles comointermediarios
PT98168A (pt) Processo para a preparacao de novos derivados do indole e de composicoes farmaceuticas que os contem
HUP0105428A2 (hu) Aril vagy heteroaril-azolilkarbinol-származékok alkalmazása a P-anyag feleslege által közvetített rendellenességek kezelésére alkalmas gyógyszerkészítmények előállítására
NZ331874A (en) Arylamino fused pyridines and pyrimidines and their use in treating psychiatric and neurological diseases
ES2111650T3 (es) Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
AR004516A1 (es) Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen
ES2071479T3 (es) Derivados de indano.
NO953543L (no) Heterosykliske forbindelser, deres anvendelse og fremstilling
ATE102626T1 (de) Heterocyclische verbindungen, ihre darstellung und verwendung.
ES2111326T3 (es) Derivados de imidazolona y oxazolona como antagonistas de dopamina.
DE69925160D1 (de) Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität
BRPI0410613A (pt) preparação de quinoxalinas substituìdas a partir da dianlina com 2,3-diidróxi-1,4-dioxano
MX9703671A (es) Compuesto de aminometil arilo y ligandos selectivos del subtipo de receptor de la dopamina.
DK1068199T3 (da) N-Aryloxyethyl-indolyl-alkylaminer til behandling af depression

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment